Concentra Group Holdings Parent, Inc. (CON) Fundamental Analysis: Bull vs. Bear Case

CON

Concentra Group Holdings Parent, Inc.

Fundamental data last updated:November 5, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Care Facilities

Exchange

NYSE

County of HQ

US

Next Earnings Date

11/05/2026

Business Summary

Concentra Group Holdings Parent, Inc. is a U.S.-based provider of occupational health solutions. The company delivers a comprehensive suite of occupational and consumer health services, encompassing treatment for workers' compensation injuries, urgent care, diagnostic clinical testing, preventative health measures, and employer-specific programs, along with wellness initiatives. These services are accessible through their network of occupational health centers and onsite clinics. Furthermore, Concentra offers specialized solutions like Concentra Telemed, a telemedicine platform for addressing work-related injuries and illnesses and supporting employer services; Concentra Pharmacy, providing pharmaceutical solutions; and Concentra Medical Compliance Administration, a third-party administrative service that assists employers in managing drug abuse testing programs for both regulated and non-regulated workforces. Established in 1979 and headquartered in Mechanicsburg, Pennsylvania, the company functions as a subsidiary of Select Medical Corporation.

VALUATION

P/E

26.02 Market Cap ($M USD)

$5.14B

Forward P/E

24.47 PEG

1.05 PRICE TO SALES

2.25 PRICE TO BOOK

10.71 EV / EBITDA

15.50 5-Year Average P/E

Free Cash Flow Yield

6.80%

DCF Value

$38.63

Graham Number

$11.53

Price to FCF

14.70 EV to FCF

20.38 Earnings Yield

3.89%

FCF Yield

6.80%

DIVIDEND

Yield

0.62%

Annual Payout

$0.25

Payout Ratio

0.01%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.57

Next Year EPS Growth Estimate

$1.65

Next Year Revenue Growth Estimate

$2.35B

Return on Equity (ROE)

47.30%

FREE CASH FLOW

Operating Margin

16.39%

Debt-to-Equity

4.49 Piotroski F-Score

8 Altman Z-Score

2.58 Return on Invested Capital (ROIC)

10.51%

Current Ratio

1.38 Quick Ratio

1.38 Net Debt to EBITDA

4.32 Interest Coverage

3.49 Gross Profit margin

29.31%

FCF PER SHARE

$2.76

REVENUE PER SHARE

$18.06

Gainseekers Quantitative Analysis

Summary

Concentra Group Holdings Parent, Inc. appears to be trading at a premium relative to its intrinsic value. The snapshot price exceeded its DCF value, suggesting the market may be overestimating future growth. With a Forward P/E of 24.39 and an Earnings Yield of 3.90%, the stock is priced for growth, yet its Altman Z-score of 2.54 indicates moderate financial distress risk. The Graham Number also suggests overvaluation, hinting at potential downside if growth expectations aren’t met. Despite these concerns, the company’s robust Return on Equity of 47.30% showcases strong management execution.

AI Exposure / Tech Reliance

Operating within the healthcare sector, Concentra is well-positioned to leverage AI advancements in medical care facilities. The industry is ripe for tech integration, offering opportunities for efficiency improvements and enhanced patient care. As AI continues to evolve, Concentra's adaptability will be crucial in maintaining its competitive edge.

The Bull Case

For the discerning GARP investor, Concentra offers compelling strengths. A Piotroski F-Score of 8 signals solid financial health, while a ROIC of 10.51% indicates efficient capital utilization. The company's Free Cash Flow Yield, though modest, complements its strong operating margin of 16.39%, suggesting effective cost management and pricing power. These metrics paint a picture of a company capable of generating consistent returns, making it an attractive option for those seeking growth at a reasonable price.

The Bear Case

However, potential investors should be wary of Concentra's structural vulnerabilities. The Price/Book ratio of 10.67 and Price/Sales ratio of 2.24 highlight a rich valuation, raising concerns about overextension. With the stock trading near its 52-week high, technical indicators suggest limited upside. Additionally, a Debt/Equity ratio of 4.49 underscores significant leverage, which could pose risks in a rising interest rate environment.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$40.71

Institutional Ownership %

1-Year Beta

0.63 Insider Buying % (6 Mo)

Distance to 52-Week High

2.95%

Distance to 52-Week Low

54.02%

EARNINGS SURPRISE %

23.34%

50-DAY SMA

$36.32

200-DAY SMA

$28.50

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.